Related Experiment Videos
[Sensitivity of penicillin-resistance pneumococci]
1Pharma-Forschung/Infectious Diseases, F. Hoffmann-La Roche AG, Basel.
Immunitat Und Infektion
|February 1, 1993
Summary
This study evaluated 53 Streptococcus pneumoniae isolates against 14 antibiotics. Rifampicin showed high activity, and combining it with beta-lactams may prevent resistance.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Antibiotic resistance in Streptococcus pneumoniae is a growing global health concern.
- Penicillin-resistant strains of S. pneumoniae pose significant treatment challenges.
- Understanding susceptibility patterns is crucial for effective antimicrobial therapy.
Purpose:
- To assess the in vitro activity of 14 antimicrobial agents against clinical isolates of Streptococcus pneumoniae.
- To investigate potential synergistic effects between beta-lactams and other antibiotics.
- To explore therapeutic strategies to overcome antibiotic resistance in S. pneumoniae.
Summary:
- Fifty-three clinical isolates of Streptococcus pneumoniae with varying penicillin G susceptibility were tested against 14 agents.
- Rifampicin demonstrated the highest in vitro activity, followed by imipenem, vancomycin, cefotaxime, ceftriaxone, Ro 23-9424, and amoxicillin.
- Combinations of beta-lactams with amikacin or rifampicin showed additive effects, with beta-lactam addition potentially inhibiting rifampicin resistance.
Impact:
- Identifies rifampicin as a potent agent against S. pneumoniae isolates.
- Suggests a combination therapy of rifampicin with a beta-lactam as a potential strategy to combat resistance.
- Provides valuable data for guiding antimicrobial selection in treating S. pneumoniae infections.